These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 9536273)

  • 21. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant.
    Ikeda K; Wakimoto H; Ichikawa T; Jhung S; Hochberg FH; Louis DN; Chiocca EA
    J Virol; 2000 May; 74(10):4765-75. PubMed ID: 10775615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glioma immunotherapy by IL-21 gene-modified cells or by recombinant IL-21 involves antibody responses.
    Daga A; Orengo AM; Gangemi RM; Marubbi D; Perera M; Comes A; Ferrini S; Corte G
    Int J Cancer; 2007 Oct; 121(8):1756-63. PubMed ID: 17582604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge.
    Osorio Y; Ghiasi H
    J Virol; 2005 Mar; 79(6):3297-308. PubMed ID: 15731224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
    Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
    J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors.
    Guffey MB; Parker JN; Luckett WS; Gillespie GY; Meleth S; Whitley RJ; Markert JM
    Cancer Gene Ther; 2007 Jan; 14(1):45-56. PubMed ID: 16990846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous RMP-7 increases delivery of ganciclovir into rat brain tumors and enhances the effects of herpes simplex virus thymidine kinase gene therapy.
    LeMay DR; Kittaka M; Gordon EM; Gray B; Stins MF; McComb JG; Jovanovic S; Tabrizi P; Weiss MH; Bartus R; Anderson WF; Zlokovic BV
    Hum Gene Ther; 1998 May; 9(7):989-95. PubMed ID: 9607410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibiotic-mediated chemoprotection enhances adaptation of E. coli PNP for herpes simplex virus-based glioma therapy.
    Bharara S; Sorscher EJ; Gillespie GY; Lindsey JR; Hong JS; Curlee KV; Allan PW; Gadi VK; Alexander SA; Secrist JA; Parker WB; Waud WR
    Hum Gene Ther; 2005 Mar; 16(3):339-47. PubMed ID: 15812229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma.
    Yuan X; Hu J; Belladonna ML; Black KL; Yu JS
    Cancer Res; 2006 Mar; 66(5):2630-8. PubMed ID: 16510582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of in situ retroviral interleukin-4 transfer on established intracranial tumors.
    Saleh M; Wiegmans A; Malone Q; Stylli SS; Kaye AH
    J Natl Cancer Inst; 1999 Mar; 91(5):438-45. PubMed ID: 10070943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.
    Ali SA; McLean CS; Boursnell ME; Martin G; Holmes CL; Reeder S; Entwisle C; Blakeley DM; Shields JG; Todryk S; Vile R; Robins RA; Rees RC
    Cancer Res; 2000 Mar; 60(6):1663-70. PubMed ID: 10749137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization and transduction of a retroviral vector encoding human interleukin-4 and herpes simplex virus-thymidine kinase for glioma tumor vaccine therapy.
    Okada H; Attanucci J; Tahara H; Pollack IF; Bozik ME; Chambers WH; Lotze MT
    Cancer Gene Ther; 2000 Mar; 7(3):486-94. PubMed ID: 10766355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
    Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
    Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
    Todo T; Martuza RL; Dallman MJ; Rabkin SD
    Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Herpes simplex virus thymidine kinase gene therapy in experimental rat BT4C glioma model: effect of the percentage of thymidine kinase-positive glioma cells on treatment effect, survival time, and tissue reactions.
    Sandmair AM; Turunen M; Tyynelä K; Loimas S; Vainio P; Vanninen R; Vapalahti M; Bjerkvig R; Jänne J; Ylä-Herttuala S
    Cancer Gene Ther; 2000 Mar; 7(3):413-21. PubMed ID: 10766347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease.
    Fernandez M; Porosnicu M; Markovic D; Barber GN
    J Virol; 2002 Jan; 76(2):895-904. PubMed ID: 11752178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18.
    Yamanaka R; Xanthopoulos KG
    DNA Cell Biol; 2005 May; 24(5):317-24. PubMed ID: 15869409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.
    Barnard Z; Wakimoto H; Zaupa C; Patel AP; Klehm J; Martuza RL; Rabkin SD; Curry WT
    Neurosurgery; 2012 Sep; 71(3):741-8; discussion 748. PubMed ID: 22653387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1.
    Jia WW; McDermott M; Goldie J; Cynader M; Tan J; Tufaro F
    J Natl Cancer Inst; 1994 Aug; 86(16):1209-15. PubMed ID: 8040888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD8+-dependent CNS demyelination following ocular infection of mice with a recombinant HSV-1 expressing murine IL-2.
    Osorio Y; La Point SF; Nusinowitz S; Hofman FM; Ghiasi H
    Exp Neurol; 2005 May; 193(1):1-18. PubMed ID: 15817260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer.
    Zager JS; Delman KA; Malhotra S; Ebright MI; Bennett JJ; Kates T; Halterman M; Federoff H; Fong Y
    Mol Med; 2001 Aug; 7(8):561-8. PubMed ID: 11591892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.